Radio ExpressTV
Live
Sothema: 2025 Marked by Strong Growth and Significant Strategic Developments
Sothema concluded 2025 with robust financial results, affirming the strength of its economic model and the effectiveness of its development strategy in the context of rising demand for health products and services.
The group’s consolidated turnover reached 3.227 billion dirhams, achieving a growth of 15 percent compared to 2024, supported by a noticeable improvement in profitability indicators, with EBITDA approaching 763 million dirhams, up by 27 percent, while the operating margin remained stable at 23.7 percent.
The group’s net result increased to 386 million dirhams, reflecting a growth of 22 percent, indicative of a balanced financial performance throughout the year.
2025 also witnessed a significant strategic shift for the group, highlighted by two major acquisitions: the purchase of “Soludia,” a company specializing in blood filtration solutions, and the procurement of the “CIALIS®” trademark rights in Morocco from “Lilly.” These moves enabled Sothema to expand its operations and strengthen its presence in promising sectors.
In this context, General Director Lamia Tazi stated that 2025 represented a critical period of growth and transformation, emphasizing that the group continues to build a model capable of achieving sustainable growth and solidifying its position in the healthcare sector at a regional level.
Commercially, the company reported positive performance across several strategic therapeutic areas, particularly in oncology, cardiology, diabetes, and autoimmune diseases, which served as primary growth drivers backed by high-value offerings.
Sothema also continued to bolster its product portfolio, launching 14 new products in 2025, including seven locally manufactured items, reaffirming its commitment to supporting national industry. Among these innovations was the introduction of a treatment for multiple sclerosis based on “Glatiramer Acetate,” a first in the country, as well as a biological drug aimed at treating multiple types of cancer.
The group saw further expansion into other medical fields, such as ophthalmology, gastroenterology, and mental health, along with intensive regulatory activity, having submitted 20 files and secured 18 marketing licenses that included innovative treatments like a cannabis-based drug for epilepsy, in addition to dietary supplements.
In terms of investment, the group allocated 85 million dirhams in 2025, excluding the “Soludia” deal, aimed at modernizing its industrial infrastructure, enhancing production capacities, and acquiring modern equipment to support future growth.
Looking ahead to 2026, Sothema plans to continue its growth trajectory by developing 25 pharmaceutical molecules currently under research and launching 30 new products in the Moroccan market, alongside maintaining its external growth strategy and developing its industrial capabilities, in a year that holds special significance as it marks the 50th anniversary of the group’s establishment.
Regarding shareholders, the board of directors has proposed a total dividend distribution of 33 dirhams per share, compared to 28 dirhams in 2024, bringing the total distributions to 252.8 million dirhams.
